Lindsay Jayne Bawden

Title: Lindsay Jayne Bawden: Innovator in Cancer Research

Introduction

Lindsay Jayne Bawden is a prominent inventor based in Oxford, GB. She has made significant contributions to the field of cancer research, particularly through her innovative patents. With a total of 3 patents, her work focuses on developing agents that can promote tumor regression and inhibit cancer cell proliferation.

Latest Patents

Bawden's latest patents include the use of MMP inhibitors, which are various known compounds that have been found useful in preparing agents for promoting tumor regression and inhibiting cancer cell proliferation. Another notable patent involves Insulin-like Growth Factor II (IGF-II) analogues, where at least one of R37 and R38 is replaced with another amino acid residue. The most preferred analogue is IGF-II R37Q R38Q, which can be produced in E. coli, unlike natural IGF-II, which is cleaved upon secretion. These analogues retain activity on the type I and type II IGF receptors but exhibit lower affinity for the insulin receptor, making them more specific in their action.

Career Highlights

Throughout her career, Bawden has worked with notable companies such as British Biotech Pharmaceuticals Limited and British Biotechnology Limited. Her work in these organizations has contributed to advancements in biopharmaceuticals and cancer treatment.

Collaborations

Bawden has collaborated with esteemed colleagues, including Richard Mark Edwards and Peter Duncan Brown. These partnerships have further enhanced her research and innovation in the field.

Conclusion

Lindsay Jayne Bawden is a trailblazer in cancer research, with a focus on developing innovative solutions to combat cancer. Her contributions through her patents and collaborations highlight her commitment to advancing medical science.